Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation

References

• Poplawska-Szczyglowska L, Walewski J, Pienkowska-Grela B, . Chronic lymphocytic leukaemia presenting with central nervous system involvement. Med Oncol 1999;16:65–68.
   PubMed Web of Science ®Google Scholar
• Kaiser U. Cerebral involvement as the initial manifestation of chronic lymphocytic leukaemia. Acta Haematol 2003;109:193–195.
   PubMed Web of Science ®Google Scholar
• Kakimoto T, Nakazato T, Hayashi R, . Bilateral occipital lobe invasion in chronic lymphocytic leukemia. J Clin Oncol 2010;28: e30–e32.
   Web of Science ®Google Scholar
• Russwurm G, Heinsch M, Radkowski R, . Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy. Blood 2010;116:2617–2618.
   PubMed Web of Science ®Google Scholar
• Tonino SH, Rijssenbeek AL, Oud ME, . Intracerebral infiltration as the unique cause of the clinical presentation of chronic lymphocytic leukemia/small lymphocytic leukemia. J Clin Oncol 2011;29: e837–e839.
   Web of Science ®Google Scholar
• Fain JS, Naeim F, Becker DP, . Chronic lymphocytic leukemia presenting as a pituitary mass lesion. Can J Neurol Sci 1992;19: 239–242.
   PubMed Web of Science ®Google Scholar
• Nimubona S, Bernard M, Morice P, . Complications of malignancy: case 3. Chronic lymphocytic leukemia presenting with panhypopituitarism. J Clin Oncol 2004;22:374–376.
   Google Scholar
• Elliott MA, Letendre L, Li CY, . Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br J Haematol 1999;104:689–694.
   PubMed Web of Science ®Google Scholar
• Kodali S, Chen C, Rathnasabapathy C, . JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res 2009;33:e236–e239.
   PubMedGoogle Scholar
• Henry L, Carillo S, Jourdan E, . Association of essential thrombocythemia and chronic lymphocytic leukemia:absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol 2007;82:500–501.
   PubMed Web of Science ®Google Scholar
• Hussein K, Brakensiek K, Ballmaier M, . B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 2006;77:539–541.
   PubMed Web of Science ®Google Scholar
• Musolino C, Allegra A, Penna G, . Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol 2009;122:46–49.
   PubMed Web of Science ®Google Scholar
• Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V617F positive essential thrombocythemia: a common defective stem cell?Leuk Res 2009;33:854–855.
   PubMed Web of Science ®Google Scholar
• Ishii T, Bruno E, Hoffman R, . Involvement of various hematopoietic-cell lineages by the JAK2V617Fmutation in polycythemia vera. Blood 2006;108:3128–3134.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Christensen JH, Hasselbalch HC, . The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007;136:745–751.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Tonetti C, . Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109: 71–77.
   PubMed Web of Science ®Google Scholar
• Kratz CP, Böll S, Kontny U, . Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381–383.
   PubMed Web of Science ®Google Scholar
• Bercovich D, Ganmore I, Scott LM, . Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484–1492.
   PubMed Web of Science ®Google Scholar
• Gaikwad A, Rye CL, Devidas M, . Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009;144:930–932.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Harvey RC, . JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009;106:9414–9418.
   PubMed Web of Science ®Google Scholar
• Levine RL, Loriaux M, Huntly BJP, . The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377–3379.
   PubMed Web of Science ®Google Scholar
• Moazzam AA, Drappatz J, Kim RY, . Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. J Neurooncol 2012;106:185–200.
   PubMed Web of Science ®Google Scholar
• Jóhannsson J, Specht L, Mejer J, . Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 2002;54:1466–1470.
   PubMed Web of Science ®Google Scholar
• Ulutin HC, Kaptan K, Beyan C. Low-dose local palliative radiotherapy in newly diagnosed chronic lymphocytic leukemia. Am J Hematol 2005;80:87.
   PubMed Web of Science ®Google Scholar